[
  {
    "doi": "10.5555/mock.medrxiv.2026.04.26.111",
    "source": "medrxiv",
    "title": "Preprint: Combined SGLT2i + Finerenone in Korean T2DM-DKD: Real-World Evidence",
    "abstract": "Korean nationwide claims analysis of 22,000 patients with T2DM-DKD found combination empagliflozin + finerenone associated with reduced all-cause mortality vs SGLT2 inhibitor alone. Hyperkalemia incidence was higher but manageable. Findings extend KDA 2025 consensus statement.",
    "jif": 0.0,
    "days_since_pub": 2
  },
  {
    "doi": "10.5555/mock.medrxiv.2026.04.26.112",
    "source": "medrxiv",
    "title": "Preprint: GLP-1 RA Class Effect on UACR in T1DM with Diabetic Nephropathy",
    "abstract": "Pooled patient-level data from three open-label studies of liraglutide and semaglutide in type 1 diabetes with diabetic nephropathy. UACR reduction averaged 24% at 12 months. Severe hypoglycemia trend was lower with semaglutide.",
    "jif": 0.0,
    "days_since_pub": 4
  },
  {
    "doi": "10.5555/mock.medrxiv.2026.04.26.113",
    "source": "medrxiv",
    "title": "Preprint: Tirzepatide-Induced eGFR Recovery in Stage 3b CKD: Mechanistic Sub-Analysis",
    "abstract": "In a sub-study of tirzepatide phase 3 in T2DM with eGFR 30-44, an early eGFR dip was followed by net recovery at 52 weeks. UACR fell 32%. No excess hyperkalemia.",
    "jif": 0.0,
    "days_since_pub": 1
  },
  {
    "doi": "10.5555/mock.medrxiv.2026.04.26.114",
    "source": "medrxiv",
    "title": "Preprint: Spironolactone vs Esaxerenone in Macroalbuminuric T2DM",
    "abstract": "Head-to-head pragmatic trial of spironolactone 25 mg vs esaxerenone 2.5 mg added to background SGLT2 inhibitor. Both reduced UACR; esaxerenone had a lower hyperkalemia rate. Power for eGFR slope was limited.",
    "jif": 0.0,
    "days_since_pub": 6
  },
  {
    "doi": "10.5555/mock.medrxiv.2026.04.26.115",
    "source": "medrxiv",
    "title": "Preprint: A Computational Pipeline for DKD Biomarker Discovery",
    "abstract": "We describe a multi-omics pipeline to nominate biomarkers for diabetic kidney disease progression. No drug intervention; mainly methodological.",
    "jif": 0.0,
    "days_since_pub": 3
  },
  {
    "doi": "10.5555/mock.medrxiv.2026.04.26.116",
    "source": "medrxiv",
    "title": "Preprint: Sotagliflozin vs Dapagliflozin on All-Cause Mortality in T2DM-DKD",
    "abstract": "Indirect comparison meta-analysis suggests sotagliflozin and dapagliflozin have comparable all-cause mortality outcomes in T2DM-DKD with eGFR 30-60. UACR reduction was similar. Authors call for direct head-to-head trial.",
    "jif": 0.0,
    "days_since_pub": 5
  }
]